Simon joined Pivotal China in 2020 as an Operating Partner. Prior to joining, served as Executive Vice President at 28-7, a start-up pioneering innovative therapeutics to modulate RNA. Prior to that, he has held strategy and business development roles of increasing responsibility at Tesaro, MedImmune/AstraZeneca, Amgen, Constellation, Massachusetts General Hospital, and L.E.K. Consulting. He enjoys the creative combination of strategic analysis and deal-making to bring meaningful change for patients. Simon’s projects have spanned pharmaceuticals, software, and medical devices across many therapeutic areas. His transactional expertise encompasses M&A, global and regional strategic collaborations, co-promotions, platform partnering, and spin-outs.
Simon received his Ph.D. in Biophysics from Harvard and a B.S. degree in Molecular Biology from the University of California, San Diego.